Patents Represented by Attorney J. Michael Schiff
-
Patent number: 7195911Abstract: The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.Type: GrantFiled: January 11, 2002Date of Patent: March 27, 2007Assignees: Geron Corporation, The Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 7175839Abstract: This invention provides medicaments and methods for managing cancer using donor cells that are alloactivated in culture. Alloactivated cells are implanted into the bed of a solid tumor and initiate a response by the host against the tumor. Subsequently, alloactivated cells are implanted into the bed of a solid tumor a second time. The two implants work synergistically to confer remarkable benefit to the treated subject, both in terms of management of the cancer and the development of an anti-cancer immune response. The beneficial effects may include regression of the tumor and extended survival. Removal of any residual tumor after the second implant facilitates ongoing resistance to tumor regrowth or metastasis.Type: GrantFiled: September 29, 1998Date of Patent: February 13, 2007Assignee: Meyer Pharmaceuticals LLCInventor: John C. Hiserodt
-
Patent number: 7091021Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. Catalytically active and inactive human telomerase reverse transcriptase variants comprising deletions or other mutations are provided.Type: GrantFiled: November 21, 2001Date of Patent: August 15, 2006Assignee: Geron CorporationInventor: Gregg B. Morin
-
Patent number: 7067283Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.Type: GrantFiled: March 26, 2004Date of Patent: June 27, 2006Assignee: Geron CorporationInventors: Scott L. Weinrich, Edward M. Atkinson, III, Serge P. Lichtsteiner, Alain P. Vasserot, Ronald A. Pruzan
-
Patent number: 7041438Abstract: This disclosure provides an improved system for culturing human pluripotent stem (pPS) cells in the absence of feeder cells. The role of the feeder cells can be replaced by supporting the culture on an extracellular matrix, and culturing the cells in a conditioned medium. Permanent cell lines are provided that can produce conditioned medium on a commercial scale. Methods have also been discovered to genetically alter pPS cells by introducing the cells with a viral vector or DNA/lipid complex. The system described in this disclosure allows for bulk proliferation of pPS cells for use in studying the biology of pPS cell differentiation, and the production of important products for use in human therapy.Type: GrantFiled: October 23, 2001Date of Patent: May 9, 2006Assignee: Geron CorporationInventors: Melissa K. Carpenter, Margaret S. Inokuma, Chunhui Xu
-
Patent number: 7033831Abstract: This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine.Type: GrantFiled: December 6, 2002Date of Patent: April 25, 2006Assignee: Geron CorporationInventors: Gregory J. Fisk, Margaret S. Inokuma
-
Patent number: 6921664Abstract: The present invention is directed to expression vectors comprising a polynucleotide that encodes a human telomerase reverse transcriptase (hTRT) protein, variant, or fragment. The present invention is also directed to host cells that comprise expression vectors comprising a polynucleotide that encodes a hTRT protein variant, or fragment.Type: GrantFiled: January 18, 2002Date of Patent: July 26, 2005Assignees: Regents of the University of Colorado, Geron CorporationInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 6921665Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. The differentiated cell populations produced are suitable for use in tissue regeneration and non-therapeutic applications such as drug screening.Type: GrantFiled: November 26, 2001Date of Patent: July 26, 2005Assignees: Roslin Institute (Edinburgh), Geron CorporationInventors: Jim McWhir, Joseph D. Gold, J. Michael Schiff
-
Patent number: 6833269Abstract: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.Type: GrantFiled: May 31, 2001Date of Patent: December 21, 2004Assignee: Geron CorporationInventor: Melissa K. Carpenter
-
Patent number: 6808880Abstract: The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.Type: GrantFiled: January 19, 2001Date of Patent: October 26, 2004Assignees: Geron Corporation, Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin Harley, William H. Andrews
-
Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
Patent number: 6800480Abstract: Methods and materials for culturing primate-derived primordial stem cells are described. In one embodiment, a cell culture medium for growing primate-derived primordial stem cells in a substantially undifferentiated state is provided which includes a low osmotic pressure, low endotoxin basic medium that is effective to support the growth of primate-derived primordial stem cells. The basic medium is combined with a nutrient serum effective to support the growth of primate-derived primordial stem cells and a substrate selected from the group consisting of feeder cells and an extracellular matrix component derived from feeder cells. The medium further includes non-essential amino acids, an anti-oxidant, and a first growth factor selected from the group consisting of nucleosides and a pyruvate salt.Type: GrantFiled: August 29, 2000Date of Patent: October 5, 2004Assignee: Geron CorporationInventors: Andrea G. Bodnar, Choy-Pik Chiu, Joseph D. Gold, Margaret Inokuma, James T. Murai, Michael D. West -
Patent number: 6787133Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.Type: GrantFiled: December 24, 2002Date of Patent: September 7, 2004Assignee: Geron CorporationInventors: Scott L. Weinrich, Edward M. Atkinson, III, Serge P. Lichtsteiner, Alain P. Vasserot, Ronald A. Pruzan
-
Patent number: 6777203Abstract: The present invention is related to novel nucleic acids comprising telomerase reverse transcriptase (TERT) cis-acting transcriptional control sequences, including TERT human and mouse promoter sequences. The present invention is further directed to methods of using these cis-acting transcriptional control sequences, for example, to drive heterologous gene sequences; to modulate the level of transcription of TERT or to isolate novel trans-acting regulatory factors which bind to and modulate the activity of a TERT promoter.Type: GrantFiled: February 4, 1999Date of Patent: August 17, 2004Assignee: Geron CorporationInventors: Gregg B. Morin, Serge P. Lichtsteiner, Alain P. Vasserot, Robert R. Adams, William H. Andrews
-
Patent number: 6767719Abstract: This invention provides for murine telomerase reverse transcriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.Type: GrantFiled: March 16, 1998Date of Patent: July 27, 2004Assignees: Geron Corporation, Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva UniversityInventors: Gregg B. Morin, Richard Allsopp, Ronald A. DePinho, Roger A. Greenberg
-
Patent number: 6673987Abstract: Pregnancy in animals such as the pig usually does not continue to term when there are only a few embryos in the uterus. Currently available technology for maintaining pregnancy involves a series of hormone injections, and the failure rate is high. It has now been discovered that pregnancy can be maintained by complementing fertile embryos in the uterus with additional embryos that aren't expected to survive the full term of the pregnancy. Particularly suitable are parthenogenetic embryos, formed by activating and diploidizing unfertilized oocytes. The carrier embryos are engrafted into the uterus of a surrogate female, and the pregnancy continues to term without further intervention—even if the number of fertile embryos are below the minimum litter size. This provides valuable biological material that can be used for transplantation, the production of pharmaceuticals, and for agricultural use.Type: GrantFiled: March 29, 2000Date of Patent: January 6, 2004Assignee: Geron CorporationInventor: Timothy J. King
-
Patent number: 6667176Abstract: This disclosure provides a system for obtaining expression libraries from primate pluripotent stem (pPS) cells. pPS cells can be maintained in vitro without requiring a layer of feeder cells to inhibit differentiation. The role of the feeder cells is replaced by several other culture conditions provided in a suitable combination. Conditions that promote pPS cell growth without differentiation include supporting the culture on an extracellular matrix, and culturing the cells in a medium conditioned by another cell type. The cDNA libraries from such cultures are devoid of transcripts of feeder cell origin, relatively uncontaminated by transcripts from differentiated cells, and can have a high proportion of full-length transcripts. Subtraction libraries can also be produced that are enriched for transcripts modulated during differentiation.Type: GrantFiled: October 10, 2000Date of Patent: December 23, 2003Assignee: Geron CorporationInventors: Walter D. Funk, Melissa K. Carpenter, Joseph D. Gold, Margaret S. Inokuma, Chunhui Xu
-
Patent number: 6642048Abstract: This invention provides media that support the growth of primate pluripotent stem cells in feeder-free culture, and cell lines useful for producing such media and other purposes. Conventionally, it has been necessary to grow pluripotent embryonic cells on feeder layers of primary embryonic fibroblasts, in order to prevent them from differentiating. It has now been discovered that standard culture media conditioned by special cell lines can be used to support proliferation of pluripotent stem cells while inhibiting differentiation in an environment free of feeder cells. This invention includes mesenchymal and fibroblast-like cell lines obtained from embryonic tissue or differentiated from embryonic stem cells. Methods for deriving such cell lines, processing media, and growing stem cells using the conditioned media are described and illustrated in this disclosure.Type: GrantFiled: July 6, 2001Date of Patent: November 4, 2003Assignee: Geron CorporationInventors: Chunhui Xu, Joseph D. Gold
-
Patent number: 6627619Abstract: The present invention provides TRT antisense oligonucleotides, methods of detecting TRT, methods of diagnosing telomerase-related conditions, methods of diagnosing and providing a prognosis for cancer, and methods of treating telomerase-related conditions, including cancer.Type: GrantFiled: September 14, 2001Date of Patent: September 30, 2003Assignees: Geron Corporation, University Technology CorporationInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 6617110Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: November 24, 2000Date of Patent: September 9, 2003Assignees: Geron Corporation, University Technology CorporationInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 6610839Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of humana diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: September 29, 1999Date of Patent: August 26, 2003Assignee: Geron CorporationInventors: Gregg B. Morin, William H. Andrews